Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
LDLR 3949 ATENOLOL CHEMBL24 PharmGKB, NCI 15453913
LDLR 3949 GEMFIBROZIL CHEMBL457 NCI 9409246
LDLR 3949 PHOTOFRIN CHEMBL594426 DrugBank 7994588, 1531856, 7661580, 1450993, 2945739
LDLR 3949 HALOPERIDOL CHEMBL54 NCI 17052361
LDLR 3949 ZIDOVUDINE CHEMBL129 NCI 8211145
LDLR 3949 SODIUM BUTYRATE CHEMBL62381 NCI 16188956
LDLR 3949 SOYBEAN OIL CHEMBL1201485 NCI 2065036
LDLR 3949 TRIBUTYRIN CHEMBL118722 NCI 16188956
LDLR 3949 CHOLESTYRAMINE CHEMBL1201625 NCI 2110363
LDLR 3949 VERAPAMIL CHEMBL6966 NCI 7683421
LDLR 3949 RETINOL CHEMBL986 NCI 2920014
LDLR 3949 COLESTIPOL HYDROCHLORIDE CHEMBL1201474 NCI 2642754
LDLR 3949 ACETYLCYSTEINE CHEMBL600 NCI 12031897
LDLR 3949 ANTIBIOTIC CHEMBL606111 NCI 9470171
LDLR 3949 EPOETIN ALFA CHEMBL1201565 NCI 9249773
LDLR 3949 HEPARIN CALCIUM CHEMBL1201513 NCI 17322644
LDLR 3949 TETRACYCLINE CHEMBL1440 NCI 9470171
LDLR 3949 CORTICOTROPIN CHEMBL1201610 NCI 11956163
LDLR 3949 GLUCAGON CHEMBL266481 NCI 2552996

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
LDLR rs688 CC atenolol efficacy no The presence of a C allele MAY be associated with BP reduction. Not significant. 50 mg/ atenolol for twelve weeks. Genotype CC is associated with response to atenolol in people with Hypertension. 15453913 655387083
LDLR rs688 CT atenolol efficacy no 50 mg/day atenolol for twelve weeks. C carriers MAY respond to this. Association was not significant. Genotype CT is associated with response to atenolol in people with Hypertension. 15453913 655387086
LDLR rs1433099 TT pravastatin efficacy not stated PROSPER study. Baseline Lipid Values, LDL-C lowering response,trial CHD and CVD outcomes were measured. The response was in terms of LDL-C lowering in men and in incident CHD and CVD risk. 40 mg/day pravastatin. Genotype TT is associated with increased response to pravastatin in people with Vascular Diseases as compared to genotype CC. 18261733 769152906
LDLR rs2738466 GG pravastatin efficacy not stated PROSPER study.Baseline Lipid Values, LDL-C lowering response,trial CHD and CVD outcomes were measured. 40 mg/day pravastatin. Genotype GG is associated with increased response to pravastatin in people with Vascular Diseases as compared to genotype AA. 18261733 769152908
LDLR rs5925 CC atorvastatin efficacy no Genotype CC is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CT + TT. 25860945 1447677505
LDLR rs5925 CC fluvastatin efficacy no as measured by decreases in LDL-cholestrol. No significant association was seen between AA, CT and TT genotypes with response. Genotype CC is not associated with response to fluvastatin as compared to genotype TT. 16103896 982045714
LDLR rs5925 CC lovastatin efficacy yes as measured by decreases in total cholesterol. Patients with the TT genotype had levels in between patients with the CC and CT genotype. Genotype CC is associated with increased response to lovastatin as compared to genotype CT. 16103896 982045615
LDLR rs688 TT lovastatin efficacy yes as measured by decreases in total cholesterol. Patients with genotype CC had decreases in between that of patients with the TT (highest decrease) or CT (lowest decrease). Genotype TT is associated with increased response to lovastatin as compared to genotype CT. 16103896 982045571
LDLR rs14158 GG peginterferon alfa-2a efficacy no This genotype is not associated with sustained virological response (SVR). Patients with the CC genotype had a rate of SVR of 84% and those with the AA or AG genotype a rate of 75%. Please note that alleles have been complemented to the plus chromosomal strand. Genotype GG is not associated with response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes AA + AG. 21572301 1444706772
LDLR rs14158 GG peginterferon alfa-2a efficacy yes This genotype is associated with sustained virological response (SVR). Patients with the GG genotype had a rate of SVR of 41% and those with the AA or AG genotype a rate of SVR of 20%. Please note that alleles have been complemented to the plus chromosomal strand. Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes AA + AG. 21572301 1444706762